This article is a retraction of:
RETRACTED: Corrigendum: Combination of Tanshinone IIA and Cisplatin Inhibits Esophageal Cancer by Downregulating NF-κB/COX-2/VEGF Pathway
Frontiers Editorial Office*A Retraction of the Correction Article
Corrigendum: Combination of Tanshinone IIA and Cisplatin Inhibits Esophageal Cancer by Downregulating NF-κB/COX-2/VEGF Pathway
by Liao, X., Gao, Y., Liu, J., Tao, L., Wang, D., Xie, D. and Mo, S. (2021). Front. Oncol. 11:670798. doi: 10.3389/fonc.2021.670798
The Journal retract the 6 April 2021 article cited above for the following reasons:
Following publication, concerns were raised regarding the integrity of the images in the published figures. The authors failed to provide a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers’ policies.
This retraction was approved by the Chief Editors of Frontiers in Oncology and the Chief Executive Editor of Frontiers. The authors did not agree to this retraction.
Citation: Frontiers Editorial Office (2021) Retraction: Corrigendum: Tan IIA Combined With DDP Inhibits Esophageal Squamous Cell Carcinoma via Down-Regulating the NF-kB/COX-2/VEGF Pathway. Front. Oncol. 11:721663. doi: 10.3389/fonc.2021.721663
Received: 07 June 2021; Accepted: 07 June 2021;
Published: 24 June 2021.
Edited and reviewed by:
Giuseppe Giaccone, Cornell University, United StatesCopyright © 2021 Frontiers Editorial Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Editorial Office, editorial.office@frontiersin.org